Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Фаза 2
Завершено
NCT03472586
| Заболевание | Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
|---|
| Статус | Завершено |
|---|
| Участники | 14 участн. |
|---|
| Вмешательство | Ipilimumab, Nivolumab, Embolization Therapy |
|---|
| Дата начала | 2.05.2018 |
|---|
| Дата завершения | 31.12.2022 |
|---|
| Публикация результатов | 29.11.2023 |
|---|
Кратко
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days. · Participants
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 8 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 5 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 1 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.